Compagnie Lombard Odier SCmA’s Inovio Pharmaceuticals INO Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-92	Closed	-$5K	–	638
2021 Q4	$5K	Hold	92	–	–	﹤0.01%	649
2021 Q3	$8K	Hold	92	–	–	﹤0.01%	605
2021 Q2	$10K	Hold	92	–	–	﹤0.01%	583
2021 Q1	$10K	Buy	+92	New	+$12.1K	﹤0.01%	603
2017 Q3	–	Sell	-167	Closed	-$16K	–	702
2017 Q2	$16K	Hold	167	–	–	﹤0.01%	630
2017 Q1	$13K	Hold	167	–	–	﹤0.01%	661
2016 Q4	$14K	Hold	167	–	–	﹤0.01%	730
2016 Q3	$19K	Hold	167	–	–	﹤0.01%	793
2016 Q2	$18K	Sell	167 -200	-54%	-$24.3K	﹤0.01%	787
2016 Q1	$38K	Buy	367 +125	+52%	+$9.65K	﹤0.01%	754
2015 Q4	$19K	Buy	+242	New	+$19.3K	﹤0.01%	805
2014 Q1	–	Sell	-177	Closed	-$25K	–	882
2013 Q4	$25K	Buy	+177	New	+$17.7K	﹤0.01%	765

Other funds holding INO

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Compagnie Lombard Odier SCmA's INO Position: Q1 2022 in Review

Compagnie Lombard Odier SCmA sold out of Inovio Pharmaceuticals (INO) in Q1 2022, closing a stake of 92 shares — an estimated $5K sold.

Compagnie Lombard Odier SCmA first reported a position in INO in Q4 2013 and held it in 12 quarters. The position peaked at $38K in Q1 2016. 198 funds tracked by Wall St. Rank hold INO as of Q1 2022.

Compagnie Lombard Odier SCmA reported no remaining Inovio Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Compagnie Lombard Odier SCmA sold 92 Inovio Pharmaceuticals shares in Q1 2022, an estimated $5K.
Compagnie Lombard Odier SCmA first reported a position in Inovio Pharmaceuticals in Q4 2013 and held it in 12 quarters.
Compagnie Lombard Odier SCmA's Inovio Pharmaceuticals position peaked at $38K in Q1 2016.
198 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2022.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q1 2022, filed 27 Apr 2022.